JP2017137289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017137289A5 JP2017137289A5 JP2016152940A JP2016152940A JP2017137289A5 JP 2017137289 A5 JP2017137289 A5 JP 2017137289A5 JP 2016152940 A JP2016152940 A JP 2016152940A JP 2016152940 A JP2016152940 A JP 2016152940A JP 2017137289 A5 JP2017137289 A5 JP 2017137289A5
- Authority
- JP
- Japan
- Prior art keywords
- risk
- cystic fibrosis
- medicament
- patient
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 66
- 201000003883 Cystic fibrosis Diseases 0.000 claims 62
- 230000002685 pulmonary effect Effects 0.000 claims 28
- 229940079593 drug Drugs 0.000 claims 26
- 239000000443 aerosol Substances 0.000 claims 21
- 239000003795 chemical substances by application Substances 0.000 claims 21
- 230000005713 exacerbation Effects 0.000 claims 20
- 210000004072 lung Anatomy 0.000 claims 17
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 16
- 150000001768 cations Chemical class 0.000 claims 15
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 13
- 208000032376 Lung infection Diseases 0.000 claims 13
- 229960003376 levofloxacin Drugs 0.000 claims 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 10
- 208000035143 Bacterial infection Diseases 0.000 claims 9
- 239000003242 anti bacterial agent Substances 0.000 claims 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims 9
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 8
- 230000003115 biocidal effect Effects 0.000 claims 8
- 229910052749 magnesium Inorganic materials 0.000 claims 8
- 239000011777 magnesium Substances 0.000 claims 8
- 229960001699 ofloxacin Drugs 0.000 claims 8
- 229940124307 fluoroquinolone Drugs 0.000 claims 7
- 210000003296 saliva Anatomy 0.000 claims 7
- 229940088710 antibiotic agent Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229910052742 iron Inorganic materials 0.000 claims 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 4
- 229910052791 calcium Inorganic materials 0.000 claims 4
- 239000011575 calcium Substances 0.000 claims 4
- 229910052802 copper Inorganic materials 0.000 claims 4
- 239000010949 copper Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000011701 zinc Substances 0.000 claims 4
- 229910052725 zinc Inorganic materials 0.000 claims 4
- 206010063659 Aversion Diseases 0.000 claims 3
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 3
- 229960003644 aztreonam Drugs 0.000 claims 3
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- 230000012953 feeding on blood of other organism Effects 0.000 claims 2
- 229960000707 tobramycin Drugs 0.000 claims 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 2
- KPPBAEVZLDHCOK-JHBYREIPSA-N (2s,3s)-3-[[(2z)-2-(2-azaniumyl-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonate;(2s)-2,6-diaminohexanoic acid Chemical group NCCCC[C@H](N)C(O)=O.O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 KPPBAEVZLDHCOK-JHBYREIPSA-N 0.000 claims 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010024264 Lethargy Diseases 0.000 claims 1
- 108010040201 Polymyxins Proteins 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 206010040744 Sinus headache Diseases 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 229950010471 aztreonam lysine Drugs 0.000 claims 1
- 230000036760 body temperature Effects 0.000 claims 1
- 229960003405 ciprofloxacin Drugs 0.000 claims 1
- 229960002549 enoxacin Drugs 0.000 claims 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229960003923 gatifloxacin Drugs 0.000 claims 1
- 229960003170 gemifloxacin Drugs 0.000 claims 1
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 claims 1
- 229960002422 lomefloxacin Drugs 0.000 claims 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 230000004199 lung function Effects 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
- 229960001180 norfloxacin Drugs 0.000 claims 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims 1
- 229960004236 pefloxacin Drugs 0.000 claims 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004954 sparfloxacin Drugs 0.000 claims 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021173092A JP2022028674A (ja) | 2016-02-05 | 2021-10-22 | 嚢胞性線維症のためのフルオロキノロン製剤 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292065P | 2016-02-05 | 2016-02-05 | |
| US62/292,065 | 2016-02-05 | ||
| US201662293554P | 2016-02-10 | 2016-02-10 | |
| US62/293,554 | 2016-02-10 | ||
| US201662348439P | 2016-06-10 | 2016-06-10 | |
| US62/348,439 | 2016-06-10 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173092A Division JP2022028674A (ja) | 2016-02-05 | 2021-10-22 | 嚢胞性線維症のためのフルオロキノロン製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017137289A JP2017137289A (ja) | 2017-08-10 |
| JP2017137289A5 true JP2017137289A5 (https=) | 2019-10-03 |
| JP6966835B2 JP6966835B2 (ja) | 2021-11-17 |
Family
ID=59500283
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016152940A Active JP6966835B2 (ja) | 2016-02-05 | 2016-08-03 | 嚢胞性線維症のためのフルオロキノロン製剤 |
| JP2021173092A Pending JP2022028674A (ja) | 2016-02-05 | 2021-10-22 | 嚢胞性線維症のためのフルオロキノロン製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021173092A Pending JP2022028674A (ja) | 2016-02-05 | 2021-10-22 | 嚢胞性線維症のためのフルオロキノロン製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210113579A1 (https=) |
| EP (1) | EP3411503A4 (https=) |
| JP (2) | JP6966835B2 (https=) |
| MA (1) | MA43981A (https=) |
| WO (1) | WO2017136516A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2346509B1 (en) | 2008-10-07 | 2020-05-13 | Horizon Orphan LLC | Inhalation of levofloxacin for reducing lung inflammation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080394B2 (en) * | 2007-04-27 | 2011-12-20 | Brigham And Women's Hospital | Method for determining predisposition to pulmonary infection |
| EP2346509B1 (en) * | 2008-10-07 | 2020-05-13 | Horizon Orphan LLC | Inhalation of levofloxacin for reducing lung inflammation |
| PT2421539T (pt) * | 2009-04-24 | 2019-11-22 | Horizon Orphan Llc | Métodos de tratamento de uma infecção bacteriana pulmonar usando fluoroquinolonas |
| RU2563809C2 (ru) * | 2009-09-04 | 2015-09-20 | Мпекс Фармасьютикалс, Инк. | Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза |
-
2016
- 2016-08-03 JP JP2016152940A patent/JP6966835B2/ja active Active
-
2017
- 2017-02-02 MA MA043981A patent/MA43981A/fr unknown
- 2017-02-02 EP EP17748127.2A patent/EP3411503A4/en not_active Withdrawn
- 2017-02-02 WO PCT/US2017/016161 patent/WO2017136516A1/en not_active Ceased
- 2017-02-02 US US16/971,945 patent/US20210113579A1/en not_active Abandoned
-
2021
- 2021-10-22 JP JP2021173092A patent/JP2022028674A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ719761A (en) | Aerosol fluoroquinolone formulations for improved pharmacokinetics | |
| JP6180012B2 (ja) | 嚢胞性線維症を治療するためのエアロゾル化レボフロキサシンの使用 | |
| JP2018513188A5 (https=) | ||
| Rahmati et al. | Fluticasone nasal spray as an adjunct to Amoxicillin for acute sinusitis in children: a randomized controlled trial | |
| JP2017137289A5 (https=) | ||
| CN102711760A (zh) | 雾化抗生素用于治疗慢性阻塞性肺病的用途 | |
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP6077725B1 (ja) | 呼吸器感染症治療剤 | |
| Mori et al. | Management of acute rhinosinusitis | |
| JP2022028674A (ja) | 嚢胞性線維症のためのフルオロキノロン製剤 | |
| Tran et al. | Burn sepsis in children | |
| TWI818910B (zh) | 吸入性肺炎、肺化膿症或肺膿瘍之治療劑 | |
| Chacko et al. | Is it the end of the road for inhaled antibiotic therapy in ventilator-associated pneumonia? | |
| HK40098387A (zh) | 吸入性肺炎、肺化脓或肺脓肿的治疗剂 | |
| Lubitz | Resolution of lung abscess due to Pseudomonas aeruginosa with oral ciprofloxacin: case report | |
| Amini et al. | A comparing study of clarithromycin XL with co-amoxiclav for treatment of chronic sinusitis; a clinical trial | |
| Anon | Treatment of acute bacterial rhinosinusitis caused by antimicrobial-resistant Streptococcus pneumoniae | |
| CN121197162A (zh) | 吸入性肺炎、肺化脓或肺脓肿的治疗剂 | |
| MX2025002408A (es) | Composicion farmaceutica en polvo seco y metodos para tratar infecciones del tracto respiratorio | |
| AU2015275224C1 (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
| CN102198133B (zh) | 一种8-二氟甲氧基氟喹诺酮及其组合物在治疗结核病中的应用 | |
| Wadhwa et al. | Therapeutic efficacy of enrofloxacin (Quinlntas) in neonatal calf pneumonia. | |
| NZ758839A (en) | Glycopeptide derivative compounds and uses thereof | |
| Schifter | Cancer and pallative care: Oral and dental manifestations, considerations and complications | |
| Braun et al. | Ciprofloxacin in respiratory tract infections: a phase IV surveillance study |